AstraZeneca's breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved ...
AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted ...
AstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial. The U.K. drugmaker evaluated its Etcamah medicine, in combination ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — AstraZeneca said Friday ...
US-listed shares of AstraZeneca dropped about 3 per cent in aftermarket trading following the news. AstraZeneca said the full trial data will be shared in due course.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results